ImmunityBio (IBRX) News Today

ImmunityBio, Inc. (NASDAQ: IBRX) shares are being lifted by a major positive development on the intellectual property front: the company announced five new U.S. patents covering its ANKTIVA + BCG cancer-treatment combination, with patent terms extending through 2035. Investors appear to be reacting favorably because the patents strengthen ImmunityBio’s moat around a key commercial asset and may support longer-term revenue potential.

• Positive Sentiment: ImmunityBio announced five U.S. patents covering the combination of ANKTIVA and BCG for cancer treatment, extending protection through 2035 and improving the company’s competitive position. Article: ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
• Positive Sentiment: Additional coverage highlighted the stock’s move higher on the patent news, reinforcing investor optimism around ANKTIVA’s commercial and pipeline value. Article: ImmunityBio stock gains on five new U.S. patent awards
• Positive Sentiment: Another report noted IBRX shares rising after the patent awards, indicating the market is treating the patent expansion as a meaningful catalyst. Article: ImmunityBio shares rise after securing five new US patents for bladder cancer therapy (IBRX)
• Neutral Sentiment: Several law firms issued reminders about the May 26 securities class-action lead-plaintiff deadline related to ImmunityBio, which keeps legal overhang in focus but is largely procedural at this stage. Article: ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
• Negative Sentiment: The company continues to face securities-fraud litigation tied to prior FDA warning concerns over allegedly unsupported cancer-treatment claims for ANKTIVA, which could weigh on sentiment if investor focus shifts back to legal risks. Article: ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline

Overall, IBRX is moving more on the patent win than on the litigation headlines today. The new patent protection is the main bullish driver because it helps defend a core product and potentially supports longer exclusivity for future sales.